Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!

Adhd, part i: thank goodness, another new drug for our kids
About the author: 

British parents have been seen dancing in the cobbled streets this week with the news that another drug has been licensed for use on children with ADHD (attention-deficit/hyperactivity disorder)

British parents have been seen dancing in the cobbled streets this week with the news that another drug has been licensed for use on children with ADHD (attention-deficit/hyperactivity disorder).

This latest saviour of their children is Strattera (generic name: atomoxetine), which will be available on prescription from July. All ADHD drugs available thus far have been the methylphenidates such as Ritalin, whereas atomoxetine is not a stimulant and so, theoretically at least, has less potential for abuse.

Atomoxetine is unlikely to steal Ritalin's thunder, and for several reasons. Paediatricians have already made it clear that the newcomer will be used only in those cases where Ritalin has failed.

For one thing, they say they are comfortable with Ritalin and understand how it works. That's simple enough to understand: it's an amphetamine-based stimulant that has a paradoxical effect, and along the way offers a range of reactions such as insomnia, anorexia, nausea, palpitations, raised blood pressure, toxic psychosis, severe depression and liver toxicity.

A sudden shift to another drug also doesn't quite fit into the game plan for Ritalin. The manufacturer has been disappointed with the take-up of the drug in Europe whereas 5 million hyperactive kids in the USA are regularly taking it, and probably will continue to do so until they reach young adulthood. Last year, the manufacturer began a major push in Europe, and especially in the UK, American paediatrician Dr Lawrence Diller has told us.

Even so, atomoxetine's approval in the UK comes as a bit of a surprise. It fared badly in a major trial last month when it was compared with Ritalin, and as reported by the National Health Service on its own website. Less than a month later and it's approved. It's life, Jim, but not as we know it.


You may also be interested in...

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2017 WDDTY Publishing Ltd.
All Rights Reserved